Edoxaban

Trade names

LIXIANA

SAVYASA

Actions

• Direct factor Xa inhibitor

Route of Administration

Oral

Bioavailability

62%

Plasma protein binding

55%

Time to peak plasma concentration

1–2 h

Half-life

10–14 h

Duration of action

24 h

Metabolism

Hepatic. Not significantly metabolised.

Elimination

Renal 50%

Interactions

P-glycoprotein inhibitors increase intestinal absorption.

Recommended dose

Stroke prophylaxis in non-valvular AF, DVT, PE:

60 mg once daily.

Reduction to 30 mg once daily is recommended in patients with one or more of the following:

• Creatinine clearance 15-50 ml/min
• Body weight ≤60 kg
• Patients on P-glycoprotein inhibiting drugs (erythromycin, ketoconazole, cyclosporin, dronedarone, etc.)

Discontinuation before invasive procedures

Should be discontinued at least 24 hours before an invasive procedure.